Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$0.95 USD
-0.07 (-6.86%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $0.92 -0.03 (-3.16%) 7:20 PM ET
2-Buy of 5 2
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BFRI 0.95 -0.07(-6.86%)
Will BFRI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BFRI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BFRI
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
BFRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Other News for BFRI
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 | BFRI ...
Biofrontera Inc. (BFRI) Announces Plan to Offer 13.6 Million Shares | BFRI Stock News
Biofrontera files to sell 13.6M shares of common stock by selling shareholders
Biofrontera Inc. files to sell 13.6M shares of common stock for holders
Biofrontera restructures relationship with Biofrontera AG, backed by $11M investment